The GABAA receptor: a novel target for treatment of fragile X?
- PMID: 17590448
- DOI: 10.1016/j.tins.2007.06.003
The GABAA receptor: a novel target for treatment of fragile X?
Abstract
GABA(A) receptors are the major inhibitory neurotransmitter receptors in the mammalian brain, implicated in anxiety, depression, epilepsy, insomnia, and learning and memory. Here, we present several lines of evidence for involvement of the GABAergic system, and in particular the GABA(A) receptor-mediated function, in fragile X syndrome, the most common form of inherited mental retardation. We argue that an altered expression of the GABA(A) receptor has neurophysiologic and functional consequences that might relate to the behavioural and neurological phenotype associated with fragile X syndrome. Interestingly, some neuropsychiatric disorders, such as anxiety, epilepsy and sleep disorders, are effectively treated with therapeutic agents that act on the GABA(A) receptor. Therefore, the GABA(A) receptor might be a novel therapeutic target for fragile X syndrome.
Similar articles
-
Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model.Behav Brain Res. 2012 Apr 1;229(1):244-9. doi: 10.1016/j.bbr.2012.01.031. Epub 2012 Jan 21. Behav Brain Res. 2012. PMID: 22285772
-
Decreased expression of the GABAA receptor in fragile X syndrome.Brain Res. 2006 Nov 22;1121(1):238-45. doi: 10.1016/j.brainres.2006.08.115. Epub 2006 Oct 16. Brain Res. 2006. PMID: 17046729
-
Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials.Neuropharmacology. 2015 Jan;88:48-54. doi: 10.1016/j.neuropharm.2014.06.028. Epub 2014 Jul 10. Neuropharmacology. 2015. PMID: 25016041 Review.
-
Involvement and therapeutic potential of the GABAergic system in the fragile X syndrome.ScientificWorldJournal. 2010 Nov 4;10:2198-206. doi: 10.1100/tsw.2010.211. ScientificWorldJournal. 2010. PMID: 21057732 Free PMC article. Review.
-
New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model.Int J Biochem Cell Biol. 2014 Aug;53:121-6. doi: 10.1016/j.biocel.2014.05.004. Epub 2014 May 14. Int J Biochem Cell Biol. 2014. PMID: 24831882 Review.
Cited by
-
Autism Spectrum Disorder with Epilepsy: A Research Protocol for a Clinical and Genetic Study.Genes (Basel). 2023 Dec 31;15(1):61. doi: 10.3390/genes15010061. Genes (Basel). 2023. PMID: 38254951 Free PMC article.
-
De novo microduplication of the FMR1 gene in a patient with developmental delay, epilepsy and hyperactivity.Eur J Hum Genet. 2012 Nov;20(11):1197-200. doi: 10.1038/ejhg.2012.78. Epub 2012 May 2. Eur J Hum Genet. 2012. PMID: 22549406 Free PMC article.
-
Potential therapeutic interventions for fragile X syndrome.Trends Mol Med. 2010 Nov;16(11):516-27. doi: 10.1016/j.molmed.2010.08.005. Epub 2010 Sep 21. Trends Mol Med. 2010. PMID: 20864408 Free PMC article. Review.
-
CGG repeat in the FMR1 gene: size matters.Clin Genet. 2011 Sep;80(3):214-25. doi: 10.1111/j.1399-0004.2011.01723.x. Epub 2011 Jun 30. Clin Genet. 2011. PMID: 21651511 Free PMC article. Review.
-
Emerging pharmacologic treatment options for fragile X syndrome.Appl Clin Genet. 2015 Apr 7;8:75-93. doi: 10.2147/TACG.S35673. eCollection 2015. Appl Clin Genet. 2015. PMID: 25897255 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
